Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Vasopressin for Septic Shock Pragmatic Trial
NCT06217562 · View on ClinicalTrials.gov ↗
Study Summary
Life-threatening low blood pressure due to a serious infection is called "septic shock." Septic shock is treated with vasopressors, medications that raise blood pressure. Sometimes first-line vasopressors are inadequate, prompting addition of a second-line vasopressor called vasopressin. However, the threshold at which to start vasopressin remains unclear. This pragmatic, cluster-randomized, cluster-crossover trial will evaluate two different strategies for septic shock treatment commonly used in current practice, comparing a lower versus a higher threshold for adding vasopressin to first-line vasopressors.
Conditions Studied
Interventions
- DRUG Vasopressin
- OTHER Recommendation to use a lower initiation threshold for vasopressin
- OTHER Recommendation to use a higher initiation threshold for vasopressin
Study Locations (13)
Utah
- American Fork Hospital — American Fork
- Cedar City Hospital — Cedar City
- Layton Hospital — Layton
- Logan Regional Hospital — Logan
- Intermountain Medical Center — Murray
- McKay-Dee Hospital — Ogden
- Park City Hospital — Park City
- Utah Valley Hospital — Provo
- Riverton Hospital — Riverton
- LDS Hospital — Salt Lake City
- Alta View Hospital — Sandy City
- St. George Regional Hospital — St. George
Idaho
- Cassia Regional Hospital — Burley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,050 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2027-12 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06217562
The ClinicalTrials.gov registry entry for NCT06217562 describes a study currently listed as active not recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2,050 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intermountain Health Care, which has 58 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Septic Shock appearing as the primary indexed condition, and to 3 interventions — of which Vasopressin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06217562 reports 13 study locations spanning 2 distinct geographic areas — top geographies include Utah, Idaho. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06217562 about?
NCT06217562 is a clinical study titled "Vasopressin for Septic Shock Pragmatic Trial". Life-threatening low blood pressure due to a serious infection is called "septic shock." Septic shock is treated with vasopressors, medications that raise blood pressure. Sometimes first-line vasopressors are inadequate, prompting addition of a second-line vasopressor called vasopressin. However, th...
What is the current status of trial NCT06217562?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 2,050 participants. The study started on 2024-02-01. Estimated completion is 2027-12.
What conditions does trial NCT06217562 study?
This clinical trial studies the following conditions: Septic Shock. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06217562?
The interventions under investigation include: Vasopressin (DRUG), Recommendation to use a lower initiation threshold for vasopressin (OTHER), Recommendation to use a higher initiation threshold for vasopressin (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06217562?
This trial is sponsored by Intermountain Health Care, which has 58 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06217562 being conducted?
This trial has 13 study locations across Idaho, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.